Company: RCUS
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001724521-25-000040
Chunk: 3

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 3
---
 (loss)— 7 (6)Comprehensive loss$(283)$(300)$(273)

See accompanying notes.

75

ARCUS BIOSCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

December 31, 2024 and 2023

(In millions, except per share amounts)

December 31,20242023ASSETS Current assets:Cash and cash equivalents$150 $127 Marketable securities828 632 Receivable from collaboration partners ($6 and $20 from a related party)20 38 Prepaid expenses and other current assets18 34 Total current assets1,016 831 Long-term marketable securities14 107 Property and equipment, net47 51 Other noncurrent assets ($— and $6 from a related party)73 106 Total assets$1,150 $1,095 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable$18 $17 Deferred revenue ($85 and $84 to a related party)85 91 Other current liabilities123 76 Total current liabilities226 184 Deferred revenue, noncurrent ($234 and $291 to a related party)234 307 Long-term debt48 — Other noncurrent liabilities157 142 Commitments (Note 17)Stockholders’ equity:Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 92.2 shares in 2024 and 75.5 shares in 2023 issued and outstanding1,617 1,311 Accumulated deficit(1,132)(849)Total stockholders’ equity485 462 Total liabilities and stockholders’ equity$1,150 $1,095 

See accompanying notes.

76

ARCUS BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Years ended December 31, 2024, 2023 and 2022

(In millions)

Number of shares of common stockCommon stock and additionalpaid-in capitalAccumulated deficit Accumulatedothercomprehensive income (loss) Totalstockholders’ equity Balance at December 31, 202170.8$1,118 $(275)$(1)$842 Issuance of common stock in connection with our equity award programs2.123 — — 23 Stock-based compensation—65 — — 65